Progress in discovery of KIF5B-RET kinase inhibitors for the treatment of non-small-cell lung cancer

Journal of Medicinal Chemistry

Volumn 58, Issue 9, 2015, Pages 3672-3681

  Song, Minsoo ^a  

^a New Drug Development Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CABOZANTINIB; KINESIN FAMILY 5B PROTEIN; LENVATINIB; LUMINESPIB; MOTESANIB; PHOSPHOTRANSFERASE INHIBITOR; PONATINIB; PROTEIN; PROTEIN RET; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; KIF5B PROTEIN, HUMAN; KINESIN; MONOCLONAL ANTIBODY;

ARTICLE; CLINICAL TRIAL (TOPIC); CRYSTAL STRUCTURE; FUSION GENE; GENE FUSION; GENETIC VARIABILITY; HUMAN; KINESIN FAMILY 5B GENE; NON SMALL CELL LUNG CANCER; ONCOGENE; REARRANGED DURING TRANSCRIPTION ONCOGENE; X RAY CRYSTALLOGRAPHY; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICAL STRUCTURE; CHEMISTRY; ENZYMOLOGY; LUNG NEOPLASMS; PROTEIN CONFORMATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; KINESIN; LUNG NEOPLASMS; MODELS, MOLECULAR; PROTEIN CONFORMATION;

EID: 84929377581     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501464c     Document Type: Article

References (53)

1. World Cancer Research Fund International. http://www.wcrf.org/index.php (accessed Jan 2, 2015).
2. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov (accessed Jan 2, 2015).
3. American Cancer Society. Cancer Facts and Figures 2014. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/ (accessed Jan 2, 2015).
4. Minuti, G.; D'Incecco, A.; Cappuzzo, F. Targeted therapy for NSCLC with driver mutations Expert Opin. Biol. Ther. 2013, 13, 1401-1412
5. Forde, P. M.; Ettinger, D. S. Targeted therapy for non-small-cell lung cancer: past, present and future Expert Rev. Anticancer Ther. 2013, 13, 745-758
6. A review on irreversible kinase inhibitors. Barf, T.; Kaptein, A. Irreversible protein kinase inhibitors: balancing the benefits and risks J. Med. Chem. 2012, 55, 6243-6262
7. U.S. Food and Drug Administration. News & Events (released Apr 29, 2014) http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm395299.htm (accessed Jan 2, 2015).
8. Pao, W.; Hutchinson, K. E. Chipping away at the lung cancer genome Nat. Med. 2012, 18, 349-351
9. Kohno, T.; Ichikawa, H.; Totoki, Y.; Yasuda, K.; Hiramoto, M.; Nammo, T.; Sakamoto, H.; Tsuta, K.; Furuta, K.; Shimada1, Y.; Iwakawa, R.; Ogiwara1, H.; Oike, T.; Enari, M.; Schetter, A. J.; Okayama, H.; Haugen, A.; Skaug, V.; Chiku, S.; Yamanaka, I.; Arai, Y.; Watanabe, S.-i.; Sekine, I.; Ogawa, S.; Harris, C. C.; Tsuda, H.; Yoshida, T.; Yokota, J.; Shibata, T. KIF5B-RET fusion in lung adenocarcinoma Nat. Med. 2012, 18, 375
10. Takeuchi, K.; Soda, M.; Togashi, Y.; Suzuki, R.; Sakata, S.; Hatano, S.; Asaka, R.; Hamanaka, W.; Ninomiya, H.; Uehara, H.; Choi, Y. L.; Satoh, Y.; Okumura, S.; Nakagawa, K.; Mano, H.; Ishikawa, Y. RET, ROS1 and ALK fusion in lung cancer Nat. Med. 2012, 18, 378-381
11. Lipson, D.; Capelletti, M.; Yelensky, R.; Otto, G.; Parker, A.; Jarosz, M.; Curran, J. A.; Balasubramanian, S.; Bloom, T.; Brennan, K. W.; Donahue, A.; Downing, S. R.; Frampton, G. M.; Garcia, L.; Juhn, F.; Mitchell1, K. C.; White, E.; White, J.; Zwirko, Z.; Peretz, T.; Nechushtan, H.; Soussan-Gutman, L.; Kim, J.; Sasaki, H.; Kim, H. R.; Park, S.-i.; Ercan, D.; Sheehan, C. E.; Ross, J. S.; Cronin, M. T.; Jänne, P. A.; Stephens, P. J. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies Nat. Med. 2012, 18, 382-384
12. Ju, Y. S.; Lee, W.-C.; Shin, J.-Y.; Lee, S.; Bleazard, T.; Won, J.-K.; Kim, Y. T.; Kim, J.-I.; Kang, J.-H.; Seo, J.-S. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing Genome Res. 2012, 22, 436-445
13. Mulligan, L. M. RET revisited: expanding the oncogenic portfolio Nat. Rev. Cancer 2014, 14, 173-186
14. Santoro, M.; Melillo, R. M.; Carlomagno, F.; Vecchio, G.; Fusco, A. Minireview: RET: Normal and abnormal functions Endocrinology 2004, 145, 5448-5451
15. https://clinicaltrials.gov (accessed Jan 2, 2015).
16. Hematology/Oncology (Cancer) Approvals & Safety Notifications. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm (accessed Jan 2, 2015).
17. Targeted Cancer Therapies. http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted (accessed Jan 2, 2015).
18. Mologni, L. Development of RET kinase inhibitors for targeted cancer therapy Curr. Med. Chem. 2011, 18, 162-175
19. Matsui, J.; Minoshima, Y.; Tsuruoka, A.; Funahashi, Y. Multi-targeted kinase inhibitor E7080 showed anti-tumor activity against medullary thyroid carcinoma and squamous thyroid carcinoma cell line based on RET and VEGFR2 tyrosine kinase inhibition. Cancer Res. 2010, 70 (8, Suppl. 1); Proceedings of the 101st Annual Meeting of AACR, Washington, DC, Apr 17-21, 2010; Abstract 3614.
20. Schlumberger, M.; Tahara, M.; Wirth, L. J.; Robinson, B.; Brose, M. S.; Elisei, R.; Dutcus, C. E.; de las Heras, B.; Zhu, J.; Habra, M. A.; Newbold, K.; Shah, M. H.; Hoff, A. O.; Gianoukakis, A. G.; Kiyota, N.; Taylor, M. H.; Kim, S.-B.; Krzyzanowska, M. K.; Sherman, S. I. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). J. Clin. Oncol. 2014, 32; ASCO Annual Meeting Abstracts, No. 15-suppl (May 20 Supplement), 2014, LBA6008.
21. Okamoto, K.; Kodama, K.; Takase, K.; Sugi, N. H.; Yamamoto, Y.; Iwata, M.; Tsuruoka, A. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models Cancer Lett. 2013, 340, 97-103
22. Carlomagno, F.; Vitagliano, D.; Guida, T.; Ciardiello, F.; Tortora, G.; Vecchio, G.; Ryan, A. J.; Fontanini, G.; Fusco, A.; Santoro, M. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases Cancer Res. 2002, 62, 7284-7290
23. Knowles, P. P.; Murray-Rust, J.; Kjær, S.; Scott, R. P.; Hanrahan, S.; Santoro, M.; Ibáñez, C. F.; McDonald, N. Q. Structure and chemical inhibition of the RET tyrosine kinase domain J. Biol. Chem. 2006, 281, 33577-33587
24. Gautschi, O.; Zander, T.; Keller, F. A.; Strobel, K.; Hirschmann, A.; Aebi, S.; Diebold, J. A patient with lung adenocarcinoma and RET fusion treated with vandetanib J. Thorac. Oncol. 2013, 8, e43-e44
25. Kim, D. W.; Jo, Y. S.; Jung, H. S.; Chung, H. K.; Song, J. H.; Park, K. C.; Park, S. H.; Hwang, J. H.; Rha, S. Y.; Kweon, G. R.; Lee, S. J.; Jo, K. W.; Shong, M. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases J. Clin. Endocrinol. Metab. 2006, 91, 4070-4076
26. Schoffski, P.; Elisei, R.; Muller, S. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline ASCO Meet. 2012, 34, 5508
27. The first paper to show clinical activity of a RET inhibitor in patients with RET -rearranged NSCLC, validating RET as a molecular target in lung cancer: Drilon, A.; Wang, L.; Hasanovic, A.; Suehara, Y.; Lipson, D.; Stephens, P.; Ross, J.; Miller, V.; Ginsberg, M.; Zakowski, M. F.; Kris, M. G.; Ladanyi, M.; Rizvi, N. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas Cancer Discovery 2013, 3, 630-635
28. De Falco, V.; Buonocore, P.; Muthu, M.; Torregrossa, L.; Basolo, F.; Billaud, M.; Gozgit, J. M.; Carlomagno, F.; Santoro, M. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer J. Clin. Endocrinol. Metab. 2013, 98, E811-E819
29. Mologni, L.; Redaelli, S.; Morandi, A.; Plaza-Menacho, I.; Gambacorti-Passerini, C. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase Mol. Cell. Endocrinol. 2013, 377 (1-2) 1-6
30. Morgillo, F.; Martinelli, E.; Troiani, T.; Orditura, M.; De Vita, F.; Ciardiello, F. Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors PLoS One 2011, 6, e28841
31. Plaza-Menacho, I.; Mologni, L.; Sala, E.; Gambacorti-Passerini, C.; Magee, A. I.; Links, T. P.; Hofstra, R. M. W.; Barford, D.; Isacke, C. M. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting J. Biol. Chem. 2007, 282, 29230-29240
32. Coxon, A.; Bready, J.; Kaufman, S.; Estrada, J.; Osgood, T.; Canon, J.; Wang, L.; Radinsky, R.; Kendall, R.; Hughes, P.; Polverino, A. Anti-tumor activity of motesanib in a medullary thyroid cancer model J. Endocrinol. Invest. 2012, 35, 181-190
33. Postgradute Cancer Research Symposium (at The University of Sydney, Nov 2013). http://sydney.edu.au/cancer-research/pdf/Final-Symposium-booklet.pdf (accessed Jan 2, 2015).
34. Fox, E.; Widemann, B. C.; Chuk, M. K.; Marcus, L. J.; Aikin, A.; Whitcomb, P.; Merino, M. J.; Lodish, M.; Dombi, E.; Steinberg, S. M.; Wells, S. A.; Balis, F. M. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma Clin. Cancer Res. 2013, 19, 4239-4248
35. Dar, A. C.; Das, T. K.; Shokat, K. M.; Cagan, R. L. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology Nature 2012, 486, 80-84
36. Elisei, R.; Schlumberger, M. J.; Müller, S. P.; Schöffski, P.; Brose, M. S.; Shah, M. H.; Licitra, L.; Jarzab, B.; Medvedev, V.; Kreissl, M. C.; Niederle, B.; Cohen, E. E.; Wirth, L. J.; Ali, H.; Hessel, C.; Yaron, Y.; Ball, D.; Nelkin, B.; Sherman, S. I. Cabozantinib in progressive medullary thyroid cancer J. Clin. Oncol. 2013, 31, 3639-3646
37. Sherman, S. I. Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer Oral Oncol. 2013, 49, 707-10
38. Houvras, Y. Completing the arc: targeted inhibition of RET in medullary thyroid cancer J. Clin. Oncol. 2012, 30, 200-202
39. Wells, S. A., Jr.; Robinson, B. G.; Gagel, R. F.; Dralle, H.; Fagin, J. A.; Santoro, M.; Baudin, E.; Elisei, R.; Jarzab, B.; Vasselli, J. R.; Read, J.; Langmuir, P.; Ryan, A. J.; Schlumberger, M. J. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial J. Clin. Oncol. 2012, 30, 134-141
40. Kurzrock, R.; Sherman, S. I.; Ball, D. W.; Forastiere, A. A.; Cohen, R. B.; Mehra, R.; Pfister, D. G.; Cohen, E. E.; Janisch, L.; Nauling, F.; Hong, D. S.; Ng, C. S.; Ye, L.; Gagel, R. F.; Frye, J.; Müller, T.; Ratain, M. J.; Salgia, R. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer J. Clin. Oncol. 2011, 29, 2660-2666
41. Blencke, S.; Zech, B.; Engkvist, O.; Greff, Z.; Orfi, L.; Horvath, Z.; Keri, G.; Ullrich, A.; Daub, H. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors Chem. Biol. 2004, 11, 691-701
42. Liu, Y.; Shah, K.; Yang, F.; Witucki, L.; Shokat, K. M. A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src Bioorg. Med. Chem. 1998, 6, 1219-1226
43. Bishop, A. C.; Ubersax, J. A.; Petsch, D. T.; Matheos, D. P.; Gray, N. S.; Blethrow, J.; Shimizu, E.; Tsien, J. Z.; Schultz, P. G.; Rose, M. D.; Wood, J. L.; Morgan, D. O.; Shokat, K. M. A chemical switch for inhibitor-sensitive alleles of any protein kinase Nature 2000, 407, 395-401
44. Ryan, A. J.; Wedge, S. R. ZD6474-a novel inhibitor of VEGFR and EGFR tyrosine kinase activity Br. J. Cancer 2005, 92 (Suppl. 1) S6-S13
45. Carlomagno, F.; Guita, T.; Anaganti, S.; Vecchio, G.; Fusco, A.; Ryan, A. J.; Billaud, M.; Santoro, M. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors Oncogene 2004, 23, 6056-6063
46. Carlomagno, F.; Santoro, M. Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer J. Chemother. 2004, 16 (Suppl. 1) 49-51
47. Dinér, P.; Alao, J. P.; Söderlund, J.; Sunnerhagen, P.; Grøtli, M. Preparation of 3-substituted-1-isopropyl-1 H -pyrazole[3,4- d ]pyrimidin-4-amines as RET kinase inhibitors J. Med. Chem. 2012, 55, 4872-4876
48. Grieco, M.; Santoro, M.; Berlingieri, M. T.; Melillo, R. M.; Donghi, R.; Bongarzone, I.; Pierotti, M. A.; Della Porta, G.; Fusco, A.; Vecchio, G. PTC is a novel rearranged form of the RET proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas Cell 1990, 60, 557-563
49. Mano, H. ALKoma: a cancer subtype with a shared target Cancer Discovery 2012, 2, 495-502
50. Soda, M.; Choi, Y. L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.-i.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; Bando, M.; Ohno, S.; Ishikawa, Y.; Aburatani, H.; Niki, T.; Sohara, Y.; Sugiyama, Y.; Mano, H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 2007, 448, 561-566
51. Christensen, J. G.; Zou, H. Y.; Arango, M. E.; Li, Q.; Lee, J. H.; McDonnell, S. R.; Yamazaki, S.; Alton, G. R.; Mroczkowski, B.; Los, G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large cell lymphoma Mol. Cancer Ther. 2007, 6, 3314-3322
52. Kohno, T.; Tsuta, K.; Tsuchihara, K.; Nakaoku, T.; Yoh, K.; Goto, K. RET fusion gene: translation to personalized lung cancer therapy Cancer Discovery 2013, 104, 1396-1400
53. Overview of Targeted Therapies for Cancer. http://www.mycancergenome.org/content/other/molecular-medicine/overview-of-targeted-therapies-for-cancer/ (accessed Jan 2, 2015).